Ally Bridge MedAlpha Master Fund L.P. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 7:02 pm Sale |
2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Ally Bridge MedAlpha Master Fund L.P. | 570,976 2.600% |
-868,403 (-60.33%) |
Filing |
| 2023-01-27 6:01 pm Purchase |
2022-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Ally Bridge MedAlpha Master Fund L.P. | 1,439,379 6.900% |
1,439,379 (New Position) |
Filing |